Eli Lilly and Company is a global pharmaceutical company founded in Indianapolis in 1876, now one of the most valuable companies in the world at ~$976B market cap. Lilly discovers, develops, manufactures, and markets medicines across diabetes, obesity, oncology, immunology, and neuroscience. It employs ~47,000 people worldwide and trades on the NYSE.
The company's transformation is best captured in a single data point: revenue grew from $28.3B in FY2021 to $65.2B in FY2025 — a 130% increase in four years driven almost entirely by its incretin / GLP-1 franchise. Mounjaro (tirzepatide), approved for type-2 diabetes in 2022, and Zepbound (tirzepatide), approved for obesity in late 2023, have become the fastest-ramping pharmaceutical products in history. FY2025 revenue grew +44.7% YoY on the back of this franchise, with gross margins expanding to 83.8% — among the highest in the pharmaceutical industry.
Beyond GLP-1, Lilly has constructed a deep pipeline: orforglipron (oral GLP-1, no injection required), donanemab (Kisunla) for early Alzheimer's, Verzenio (abemaciclib) for early breast cancer, and a growing hematology portfolio anchored by Jaypirca (pirtobrutinib). The company invested $7.8B in capex in FY2025 (and $8.4B in FY2024) to build manufacturing capacity at unprecedented speed, and has recently signed a $1.9B gene-editing licensing deal with Ascidian Therapeutics and a ~$3B collaboration with Haisco Pharmaceutical — evidence that the business development pipeline is as active as the clinical one.
Investment Thesis
Lilly is the structurally dominant player in obesity and diabetes pharmacotherapy, the largest new drug market in history. The incretin/GLP-1 TAM is projected to exceed $150B annually by the early 2030s, and tirzepatide's clinical profile — superior weight loss vs. semaglutide (Novo Nordisk's Wegovy) in head-to-head trials — gives Lilly the best-in-class label. Zepbound prescriptions are scaling into a manufacturing base that is still catching up to demand.
Three structural growth levers compound the base case: (1) Oral GLP-1 (orforglipron) — a once-daily pill that eliminates the injection barrier, expanding the addressable market from injection-willing patients to the full obese/overweight population (>1 billion globally); (2) Donanemab (Kisunla) for early Alzheimer's — the first meaningful amyloid-clearing therapy to show functional benefit in a Phase 3 trial, with FDA approval and a large, unaddressed patient population; (3) Manufacturing scale-up — Lilly is committing $50B+ in U.S. manufacturing capacity through 2030, which positions it to defend supply and margins against biosimilar entrants and regulatory pricing pressure.
The valuation framing: At 47x TTM P/E, LLY is priced as a growth compounder, not a mature pharma name. The forward P/E drops to ~29.7x on FY2026E EPS of $36.57 and ~24.4x on FY2027E EPS of $44.56 — a PEG ratio below 1x against 30%+ consensus revenue CAGRs. The premium is warranted by the franchise quality; the risk is whether growth sustains at the rate needed to absorb the multiple. Competition from Novo Nordisk (Wegovy/Ozempic), pricing pressure from the IRA, and manufacturing execution are the key bear variables.
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $28.3B | $28.5B | $34.1B | $45.0B | $65.2B |
| Revenue Growth | — | +0.8% | +19.6% | +32.0% | +44.7% |
| Gross Profit | $21.0B | $21.9B | $27.0B | $36.6B | $54.6B |
| Gross Margin | 74.2% | 76.8% | 79.2% | 81.3% | 83.8% |
| Operating Income | $7.9B | $8.7B | $10.8B | $17.5B | $29.7B |
| Operating Margin | 28.0% | 30.3% | 31.6% | 38.9% | 45.6% |
| EBITDA | $8.0B | $8.7B | $8.6B | $15.2B | $27.9B |
| EBITDA Margin | 28.4% | 30.3% | 25.1% | 33.8% | 42.9% |
| Net Income | $5.6B | $6.2B | $5.2B | $10.6B | $20.6B |
| Net Margin | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% |
| EPS (Diluted) | $5.85 | $6.57 | $5.80 | $11.71 | $22.95 |
| R&D Expense | $6.9B | $7.2B | $9.3B | $11.0B | $13.3B |
| R&D % of Revenue | 24.5% | 25.2% | 27.3% | 24.4% | 20.5% |
| Interest Expense | $340M | $332M | $486M | $781M | $795M |
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $3.8B | $2.1B | $2.8B | $3.3B | $7.2B |
| Total Current Assets | $18.5B | $18.0B | $25.7B | $32.7B | $55.6B |
| PP&E, net | $9.0B | $10.1B | $12.9B | $17.1B | $24.7B |
| Total Assets | $48.8B | $49.5B | $64.0B | $78.7B | $112.5B |
| Total Debt | $16.9B | $16.2B | $25.2B | $33.6B | $42.5B |
| Net Debt | $13.1B | $14.2B | $22.4B | $30.4B | $35.3B |
| Stockholders' Equity | $9.0B | $10.6B | $10.8B | $14.2B | $26.5B |
| Goodwill & Intangibles | $11.6B | $11.3B | $11.8B | $11.9B | $12.4B |
| Current Ratio | 1.23x | 1.05x | 0.94x | 1.15x | 1.58x |
| Debt / Equity | 1.88x | 1.52x | 2.34x | 2.37x | 1.60x |
| Net Debt / EBITDA | 1.62x | 1.64x | 2.62x | 1.99x | 1.27x |
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $7.4B | $7.6B | $4.2B | $8.8B | $16.8B |
| Capital Expenditures | ($2.0B) | ($1.9B) | ($7.4B) | ($8.4B) | ($7.8B) |
| Free Cash Flow | $5.4B | $4.6B | ($3.2B) | $0.4B | $9.0B |
| FCF Margin | 19.0% | 16.1% | −9.2% | 0.9% | 13.8% |
| Capex % of Revenue | 7.0% | 6.5% | 21.7% | 18.7% | 12.0% |
| Share Repurchases | ($1.3B) | ($1.5B) | ($0.8B) | ($2.5B) | ($4.1B) |
| Dividends Paid | ($3.1B) | ($3.5B) | ($4.1B) | ($4.7B) | ($5.4B) |
| D&A | $1.5B | $1.5B | $1.5B | $1.8B | $2.0B |
| Stock-Based Compensation | $343M | $371M | $629M | $646M | $626M |
| Net Debt Issuance | $501M | ($62M) | $8.6B | $8.9B | $8.1B |
| Multiple | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 (current $) |
|---|---|---|---|---|---|
| P/E (TTM) | 47.2x | 55.7x | 100.0x | 65.7x | 47.4x |
| EV/EBITDA | 34.4x | 41.8x | 63.8x | 47.7x | 36.2x |
| P/Sales | 9.3x | 12.2x | 15.4x | 15.4x | 15.0x |
| P/FCF | 48.9x | 75.6x | — | — | 108.8x |
| P/Book | 29.3x | 32.6x | 48.7x | 49.0x | 36.8x |
| EV/Sales | 9.8x | 12.7x | 16.0x | 16.1x | 15.5x |
| Dividend Yield | 1.17% | 1.02% | 0.78% | 0.67% | 0.64% |
| Fwd P/E (FY2026E) | — | 29.7x | |||
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Return on Equity | 62.2% | 58.6% | 48.6% | 74.6% | 77.8% |
| Return on Assets | 11.4% | 12.6% | 8.2% | 13.5% | 18.4% |
| Return on Invested Capital | 20.4% | 23.5% | 19.8% | 26.4% | 30.2% |
| Return on Capital Employed | 23.5% | 26.7% | 29.4% | 34.8% | 38.4% |
| Asset Turnover | 0.58x | 0.58x | 0.53x | 0.57x | 0.58x |
| Interest Coverage (EBIT/Int Exp) | 19.1x | 21.6x | 14.5x | 17.2x | 33.2x |
| FCF Conversion (FCF/NI) | 96.5% | 73.7% | — | 3.9% | 43.5% |
| Gross Profit / Employee (est.) | $452K | $471K | $582K | $779K | $1.16M |
| R&D Intensity (R&D / Rev) | 24.5% | 25.2% | 27.3% | 24.4% | 20.5% |
| Metric | FY2026E | FY2027E | FY2028E |
|---|---|---|---|
| Revenue (avg) | $84.8B | $98.2B | $110.1B |
| Rev Growth (implied) | +30.1% | +15.8% | +12.1% |
| EBITDA (avg) | $27.2B | $31.5B | $35.3B |
| Net Income (avg) | $31.1B | $37.7B | $44.7B |
| EPS (avg, diluted) | $36.57 | $44.56 | $51.34 |
| Fwd P/E (at $1,087) | 29.7x | 24.4x | 21.2x |
| # Analysts (Rev / EPS) | 18 / 16 | 21 / 16 | 23 / 9 |
| Date | Name | Title | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-18 | Sulzberger Gabrielle | Director | Award | 5.0 | $988.09 |
| 2026-05-18 | Luciano Juan R | Director | Award | 16.1 | $988.09 |
| 2026-05-18 | Fyrwald J Erik | Director | Award | 10.0 | $988.09 |
| 2026-05-18 | Alvarez Ralph | Director | Award | 12.6 | $988.09 |
| 2026-05-06 | Lilly Endowment Inc | Former 10% Shareholder | Sale | 15,828 | ~$995 |
- Obesity TAM sustains at $150B+. Tirzepatide (Zepbound) retains best-in-class weight-loss efficacy, Lilly grows market share vs. semaglutide/Wegovy, and manufacturing capacity expansion reaches the demand ceiling. Revenue grows toward $130B by FY2030 (consensus range $122–140B), justifying continued premium valuation.
- Orforglipron is a category expander. An oral GLP-1 pill removes the injection barrier for the broadest possible patient population. Phase 3 readouts in 2026-27 showing non-inferior weight loss to injectable GLP-1s would add an entirely new addressable cohort and blunt any generic biosimilar risk.
- Donanemab becomes a blockbuster. Kisunla (donanemab) for early Alzheimer's has FDA approval and clinical proof of amyloid clearance + functional slowing. As diagnostic infrastructure scales, the addressable patient pool expands significantly. Combined with GLP-1, it creates two independent multi-billion product lines.
- Margin expansion compounds the P/E rerating. As revenue scales toward $100B+, operating leverage drives EBITDA margins toward 45–50%. At $44+ forward EPS and 35x P/E on sustained growth, the stock reaches $1,500–$1,700.
- Multiple compression is the dominant risk. At 47x TTM P/E, any miss to the revenue or EPS trajectory results in a double-hit: lower earnings AND a lower multiple applied to them. A single guidance cut of $5B in FY2026 revenue could erase $100B+ of market cap.
- Novo Nordisk narrows the gap. Semaglutide s.c. (Wegovy) and the oral form (Rybelsus) compete directly. Novo's pipeline (CagriSema, amycretin) could challenge tirzepatide's weight-loss superiority. Pricing pressure and PBM negotiations in a duopoly market compress net pricing well below list.
- IRA drug pricing creates a structural ceiling. The Inflation Reduction Act allows Medicare price negotiation for high-revenue drugs. Tirzepatide — already at this revenue scale — is an obvious target. A 20–50% mandated price cut vs. current list prices materially impairs the long-run revenue ceiling.
- Manufacturing execution and net debt. Lilly added $22B in net debt since FY2021 to fund capacity expansion. Capex of $7–8B/year suppresses FCF conversion. If demand growth slows before capacity is fully utilized, the levered build becomes a drag on returns rather than an accelerant.
Scenarios framed on forward P/E applied to FY2026E EPS of $36.57 (avg consensus, 16 analysts). The swing variables are (1) incretin franchise volume/market share vs. Novo, (2) orforglipron Phase 3 news flow, (3) IRA/pricing developments, and (4) manufacturing execution. At current prices, the bear case hinge is multiple compression, not an absolute earnings decline.
- FY2026E EPS: ~$40–42 (beat)
- Fwd P/E applied: ~35x
- Orforglipron Ph3 positive readout
- Zepbound supply matches demand
- No IRA pricing action in 2026
- FY2026E EPS: ~$36–38 (in-line)
- Fwd P/E applied: ~34–35x
- GLP-1 growth continues at +30%
- Manufacturing keeps pace with Rx
- In line with analyst consensus PT
- FY2026E EPS: ~$28–32 (guide cut)
- Multiple rerates to ~27–28x
- Novo narrows efficacy gap materially
- IRA pricing action announced
- Manufacturing delay delays supply
This report was generated using FMP financial data as of June 3, 2026. This is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.